Rick Gonzalez, CEO of AbbVie (AP Images)

Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

While Ab­b­Vie’s Hu­mi­ra still holds the crown for the best-sell­ing non-Covid drug last year, the Big Phar­ma has its eyes on Hu­mi­ra’s po­ten­tial suc­ces­sor. Scratch that, suc­ces­sors.

Ab­b­Vie CEO Rick Gon­za­lez told in­vestors and an­a­lysts on the phar­ma’s Q4 call this morn­ing that Ab­b­Vie ex­pects to add sev­er­al new in­di­ca­tions to Skyrizi and Rin­voq’s “list of ap­proved us­es” over the next few months. For Skyrizi, they got the FDA’s OK a few weeks ago to use the drug for pso­ri­at­ic arthri­tis — and they’re al­so look­ing for the thumbs up from the agency on Crohn’s dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.